PGP and cancer: This is probably due to the other resistant factors (except the overexpression of P-gp) of different chemotherapeutics on different cancer cells, and/or different levels of P-gp, suggesting that higher transporter expression levels may require a higher inhibitor concentration to achieve a certain inhibitory effect [41,42].